Technical Analysis for GNTA - Genenta Science S.p.A.

Grade Last Price % Change Price Change
C 4.70 0.00% 0.00
GNTA closed down 4.86 percent on Wednesday, November 20, 2024, on 54 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Lower Bollinger Band Touch Weakness 0.00%
180 Bullish Setup Bullish Swing Setup -4.86%
NR7 Range Contraction -4.86%
NR7-2 Range Contraction -4.86%
Narrow Range Bar Range Contraction -4.86%
NR7 Range Contraction -4.08%
Narrow Range Bar Range Contraction -4.08%
Inside Day Range Contraction -4.08%
20 DMA Resistance Bearish -6.37%

   Recent Intraday Alerts

Alert Time
Gap Up Closed about 1 hour ago
60 Minute Opening Range Breakdown about 1 hour ago
50 DMA Resistance about 1 hour ago
10 DMA Resistance about 1 hour ago
Down 2 % about 1 hour ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Gene Therapy Cell Biology Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme

Is GNTA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.28
52 Week Low 2.2
Average Volume 15,811
200-Day Moving Average 3.99
50-Day Moving Average 4.80
20-Day Moving Average 5.05
10-Day Moving Average 4.89
Average True Range 0.46
RSI (14) 44.13
ADX 16.65
+DI 14.26
-DI 20.50
Chandelier Exit (Long, 3 ATRs) 4.25
Chandelier Exit (Short, 3 ATRs) 5.83
Upper Bollinger Bands 5.53
Lower Bollinger Band 4.57
Percent B (%b) 0.14
BandWidth 19.06
MACD Line -0.05
MACD Signal Line 0.00
MACD Histogram -0.0482
Fundamentals Value
Market Cap 85.62 Million
Num Shares 18.2 Million
EPS -0.78
Price-to-Earnings (P/E) Ratio -6.03
Price-to-Sales 0.00
Price-to-Book 2.22
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.47
Resistance 3 (R3) 5.46 5.21 5.34
Resistance 2 (R2) 5.21 5.01 5.21 5.29
Resistance 1 (R1) 4.95 4.89 4.83 4.96 5.25
Pivot Point 4.70 4.70 4.63 4.70 4.70
Support 1 (S1) 4.44 4.50 4.32 4.45 4.15
Support 2 (S2) 4.19 4.38 4.19 4.11
Support 3 (S3) 3.93 4.19 4.06
Support 4 (S4) 3.94